Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aardvark Therapeutics, Inc.AARD · Entity 6598 | Director | August 14, 2026 | August 21, 2026 |
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director | June 23, 2022 | June 27, 2022 |
| Eikon Therapeutics, Inc.EIKN · Entity 5380 | Chief Medical Officer | March 02, 2026 | March 04, 2026 |
| Natera, Inc.NTRA · Entity 2635 | Director | June 26, 2026 | July 01, 2026 |
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 15, 2026 | May 15, 2026 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Director | June 12, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aardvark Therapeutics, Inc.
Report date August 14, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.54 · Expires 2036-08-14 | Direct | 44,964 |
Reported balance
After 2026-08-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 44,964 · Balance 44,964 F1: The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive.
Atara Biotherapeutics, Inc.
Report date June 23, 2022 · Filed June 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,500 |
Reported balance
After 2022-06-23 transaction · row 1
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 20,500 · Balance 43,500 F1: These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.35 · Expires 2032-06-22 | Direct | 31,500 |
Reported balance
After 2022-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-23 · Grant · Acquired 31,500 · Balance 31,500 F2: The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
F2: The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
Eikon Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.88 · Expires 2036-03-01 | Direct | 134,088 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 134,088 · Balance 134,088 F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.
Natera, Inc.
Report date June 26, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,158 |
Ending reported balance
After 2026-06-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-26 · Grant · Acquired 1,571 · Balance 20,083 F1: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 11, 2027. The RSUs will become fully vested in the event that the Issuer is subject to a change in control. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-06-26 · Grant · Acquired 75 · Balance 20,158 F3: Represents the issuance of RSUs to the Reporting Person in lieu of quarterly retainer fees of $16,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 11, 2027. The RSUs will become fully vested in the event that the Issuer is subject to a change in control.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3: Represents the issuance of RSUs to the Reporting Person in lieu of quarterly retainer fees of $16,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance.
Nurix Therapeutics, Inc.
Report date May 15, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.86 · Expires 2036-05-14 | Direct | 31,250 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 31,250 · Balance 31,250 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Travere Therapeutics, Inc.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,500 |
Ending reported balance
After 2026-06-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-12 · Exercise / conversion · Acquired 4,500 · Balance 46,000 Row 2 · 2026-06-12 · Sale · Disposed 4,500 · Balance 41,500 F1: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.38 · Expires 2032-05-11 | Direct | 0 |
Reported balance
After 2026-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-12 · Exercise / conversion · Disposed 4,500 · Balance 0 F2: The stock option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.
F2: The stock option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 21, 2026 23:45 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | GrantStock Option (right to buy) · Derivative | 44,964 | $0.00 Strike: $6.54 | $0.00 |
DisclosureSEC source: 0001193125-26-361482 · ownership.xml · derivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,964 Underlying: Common Stock · 44,964 shares Expires 2036-08-14 F1 · derivative.exercise_date: The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive. Read SEC document |
| June 26, 2026 Filed Jul 1, 2026 00:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 75 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001680739-26-000015 · form4-06302026_080601.xml · nonDerivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,158 F3 · shares: Represents the issuance of RSUs to the Reporting Person in lieu of quarterly retainer fees of $16,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 26, 2026 Filed Jul 1, 2026 00:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 1,571 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001680739-26-000015 · form4-06302026_080601.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,083 F1 · shares: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 11, 2027. The RSUs will become fully vested in the event that the Issuer is subject to a change in control. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:42 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock option (right to buy) · Derivative | 4,500 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001680739-26-000014 · form4-06162026_080649.xml · derivative · entry 3 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires 2032-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:42 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 4,500 | $50.00 | $225,000.00 |
DisclosureSEC source: 0001680739-26-000014 · form4-06162026_080649.xml · nonDerivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,500 F1 · kind: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:42 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 4,500 | $21.38 | $96,210.00 |
DisclosureSEC source: 0001680739-26-000014 · form4-06162026_080649.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 12,000 | $0.00 Strike: $42.26 | $0.00 |
DisclosureSEC source: 0001680739-26-000012 · form4-05212026_050501.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-05-19 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001680739-26-000012 · form4-05212026_050501.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,500 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 15, 2026 Filed May 15, 2026 21:42 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 31,250 | $0.00 Strike: $15.86 | $0.00 |
DisclosureSEC source: 0001680739-26-000010 · wk-form4_1778881334.xml · derivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2036-05-14 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock option (right to buy) · Derivative | 4,500 | $0.00 Strike: $18.27 | $0.00 |
DisclosureSEC source: 0001680739-26-000008 · form4-05062026_080518.xml · derivative · entry 3 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires 2031-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 4,500 | $46.65 | $209,925.00 |
DisclosureSEC source: 0001680739-26-000008 · form4-05062026_080518.xml · nonDerivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,500 F1 · kind: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 4,500 | $18.27 | $82,215.00 |
DisclosureSEC source: 0001680739-26-000008 · form4-05062026_080518.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock option (right to buy) · Derivative | 9,750 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001680739-26-000007 · form4-05042026_080519.xml · derivative · entry 3 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,750 Underlying: Common Stock · 9,750 shares Expires 2034-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 9,750 | $44.22 | $431,145.00 |
DisclosureSEC source: 0001680739-26-000007 · form4-05042026_080519.xml · nonDerivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,500 F1 · kind: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:27 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 9,750 | $6.82 | $66,495.00 |
DisclosureSEC source: 0001680739-26-000007 · form4-05042026_080519.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2026 Filed Apr 29, 2026 00:35 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 83 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001680739-26-000006 · form4-04282026_080401.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,512 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $16,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock option (right to buy) · Derivative | 6,750 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001680739-26-000005 · form4-04162026_040405.xml · derivative · entry 12 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 6,750 shares Expires 2033-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock option (right to buy) · Derivative | 4,500 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001680739-26-000005 · form4-04162026_040405.xml · derivative · entry 11 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2032-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock option (right to buy) · Derivative | 4,500 | $0.00 Strike: $18.27 | $0.00 |
DisclosureSEC source: 0001680739-26-000005 · form4-04162026_040405.xml · derivative · entry 10 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2031-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0001680739-26-000005 · form4-04162026_040405.xml · derivative · entry 9 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2030-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001680739-26-000005 · form4-04162026_040405.xml · derivative · entry 8 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2029-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 6,750 | $42.12 | $284,310.00 |
DisclosureSEC source: 0001680739-26-000005 · form4-04162026_040405.xml · nonDerivative · entry 7 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,500 F1 · kind: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 26,000 | $41.07 | $1,067,820.00 |
DisclosureSEC source: 0001680739-26-000005 · form4-04162026_040405.xml · nonDerivative · entry 6 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,250 F1 · kind: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 6,750 | $17.11 | $115,492.50 |
DisclosureSEC source: 0001680739-26-000005 · form4-04162026_040405.xml · nonDerivative · entry 5 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 4,500 | $21.38 | $96,210.00 |
DisclosureSEC source: 0001680739-26-000005 · form4-04162026_040405.xml · nonDerivative · entry 4 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 4,500 | $18.27 | $82,215.00 |
DisclosureSEC source: 0001680739-26-000005 · form4-04162026_040405.xml · nonDerivative · entry 3 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 9,000 | $15.43 | $138,870.00 |
DisclosureSEC source: 0001680739-26-000005 · form4-04162026_040405.xml · nonDerivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 8,000 | $17.94 | $143,520.00 |
DisclosureSEC source: 0001680739-26-000005 · form4-04162026_040405.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 22:17 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.52 | $0.00 |
DisclosureSEC source: 0001680739-26-000003 · form4-04072026_100418.xml · derivative · entry 3 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 22:17 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 10,000 | $33.00 | $330,000.00 |
DisclosureSEC source: 0001680739-26-000003 · form4-04072026_100418.xml · nonDerivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,500 F1 · kind: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 9, 2018. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 22:17 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $26.52 | $265,200.00 |
DisclosureSEC source: 0001680739-26-000003 · form4-04072026_100418.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:59 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | GrantStock Option (Right to Buy) · Derivative | 134,088 | $0.00 Strike: $14.88 | $0.00 |
DisclosureSEC source: 0001193125-26-091770 · ownership.xml · derivative · entry 1 Baynes Roy D. · CIK 0001680739 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,088 Underlying: Common Stock · 134,088 shares Expires 2036-03-01 F1 · derivative.exercise_date: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date. Read SEC document |
| January 30, 2026 Filed Feb 4, 2026 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 70 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001680739-26-000001 · form4-02032026_080202.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,429 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $16,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 20, 2025 Filed Nov 22, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionStock Option (right to buy) · Derivative | 7,068 | $0.00 Strike: $41.19 | $0.00 |
DisclosureSEC source: 0001680739-25-000007 · form4-11212025_081101.xml · derivative · entry 14 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,068 shares Expires 2032-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option shares are fully exercisable. Read SEC document |
| November 20, 2025 Filed Nov 22, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionStock Option (right to buy) · Derivative | 600 | $0.00 Strike: $40.93 | $0.00 |
DisclosureSEC source: 0001680739-25-000007 · form4-11212025_081101.xml · derivative · entry 13 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600 shares Expires 2030-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option shares are fully exercisable. Read SEC document |
| November 20, 2025 Filed Nov 22, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,884 | $224.89 | $423,685.22 |
DisclosureSEC source: 0001680739-25-000007 · form4-11212025_081101.xml · nonDerivative · entry 11 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,359 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2025. F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.72 to $224.92 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2025 Filed Nov 22, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,900 | $223.90 | $425,417.03 |
DisclosureSEC source: 0001680739-25-000007 · form4-11212025_081101.xml · nonDerivative · entry 10 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,243 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2025. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.49 to $224.41 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2025 Filed Nov 22, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,800 | $222.90 | $401,220.00 |
DisclosureSEC source: 0001680739-25-000007 · form4-11212025_081101.xml · nonDerivative · entry 9 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,143 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2025. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.46 to $223.24 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2025 Filed Nov 22, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 900 | $221.81 | $199,631.97 |
DisclosureSEC source: 0001680739-25-000007 · form4-11212025_081101.xml · nonDerivative · entry 8 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,943 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2025. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.42 to $222.24 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2025 Filed Nov 22, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,184 | $220.14 | $260,646.00 |
DisclosureSEC source: 0001680739-25-000007 · form4-11212025_081101.xml · nonDerivative · entry 7 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,843 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2025. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.43 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2025 Filed Nov 22, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 7,068 | $41.19 | $291,130.92 |
DisclosureSEC source: 0001680739-25-000007 · form4-11212025_081101.xml · nonDerivative · entry 6 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2025 Filed Nov 22, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 600 | $40.93 | $24,558.00 |
DisclosureSEC source: 0001680739-25-000007 · form4-11212025_081101.xml · nonDerivative · entry 5 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2025 Filed Nov 22, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionStock Option (right to buy) · Derivative | 5,112 | $0.00 Strike: $40.93 | $0.00 |
DisclosureSEC source: 0001680739-25-000007 · form4-11212025_081101.xml · derivative · entry 12 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 5,112 shares Expires 2030-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option shares are fully exercisable. Read SEC document |
| November 19, 2025 Filed Nov 22, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 2,135 | $216.07 | $461,303.69 |
DisclosureSEC source: 0001680739-25-000007 · form4-11212025_081101.xml · nonDerivative · entry 4 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,359 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2025. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.55 to $216.39 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 19, 2025 Filed Nov 22, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,727 | $214.79 | $370,945.96 |
DisclosureSEC source: 0001680739-25-000007 · form4-11212025_081101.xml · nonDerivative · entry 3 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,494 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.35 to $215.30 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 19, 2025 Filed Nov 22, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,250 | $213.47 | $266,838.75 |
DisclosureSEC source: 0001680739-25-000007 · form4-11212025_081101.xml · nonDerivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,221 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.18 to $214.1550 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 19, 2025 Filed Nov 22, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 5,112 | $40.93 | $209,234.16 |
DisclosureSEC source: 0001680739-25-000007 · form4-11212025_081101.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2025 Filed Nov 5, 2025 02:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 93 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001680739-25-000005 · form4-11042025_091101.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,359 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $16,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| July 25, 2025 Filed Jul 30, 2025 01:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-020514 · form4-07292025_090701.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,266 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $16,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 27, 2025 Filed Jul 2, 2025 01:15 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 2,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-018834 · form4-07012025_090701.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,158 F1 · shares: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 12, 2026. The RSUs will become fully vested in the event that the Issuer is subject to a change in control. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.